Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
04 March 2024 - 5:00PM
UK Regulatory
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen
Healthcare Investor Conferences
Saint-Herblain (France), March 4, 2024 – Valneva SE (Nasdaq:
VALN; Euronext Paris: VLA), a specialty vaccine company, today
announced that its senior management will participate at upcoming
investor conferences in the United States and Europe. CEO Thomas
Lingelbach will present Valneva at the TD Cowen 44th Annual Health
Care Conference, taking place March 4 - 6, 2024, in Boston, MA. Mr.
Lingelbach and CFO Peter Bühler will also meet with institutional
investors during the Van Lanschot Kempen Life Sciences Conference,
held April 16 - 17, 2024, in Amsterdam, The Netherlands.
Management will discuss Valneva’s growing
commercial business and pipeline of infectious disease vaccines.
IXCHIQ®, Valneva’s third commercial product and the
world’s first approved vaccine against chikungunya virus was
recently recommended for use by the U.S. CDC Advisory Committee on
Immunization Practices (ACIP)1 and is launching in 2024.
The single-shot vaccine is also under regulatory review in Canada
and Europe and was granted accelerated assessment by the European
Medicine Agency’s Committee for Medicinal Products for Human Use
(CHMP). A decision for both submissions is expected mid-2024.
VLA15, the Company’s Lyme disease vaccine candidate, is currently
in Phase 3 clinical development and partnered with Pfizer for this
study and global commercialization. Recruitment completion for the
study was announced in December 2023.
About
IXCHIQ®
In the U.S., IXCHIQ® is a
live-attenuated vaccine indicated for the prevention of disease
caused by chikungunya virus (CHIKV) in individuals 18 years of age
and older who are at increased risk of exposure to CHIKV. As for
all products approved under FDA’s accelerated approval pathway,
continued approval for this indication is contingent upon
verification and description of clinical benefit in confirmatory
studies.
Please click
here for full Prescribing Information for
IXCHIQ®.
About Valneva SE
We are a specialty vaccine company that
develops, manufactures, and commercializes prophylactic vaccines
for infectious diseases addressing unmet medical needs. We take a
highly specialized and targeted approach, applying our deep
expertise across multiple vaccine modalities, focused on providing
either first-, best- or only-in-class vaccine solutions.
We have a strong track record, having advanced
multiple vaccines from early R&D to approvals, and currently
market three proprietary travel vaccines as well as certain
third-party vaccines leveraging our established commercial
infrastructure.
Revenues from our growing commercial business
help fuel the continued advancement of our vaccine pipeline. This
includes the only Lyme disease vaccine candidate in advanced
clinical development, which is partnered with Pfizer, as well as
vaccine candidates against the Zika virus and other global public
health threats.
Valneva Investor and Media Contacts
Laetitia Bachelot-Fontaine
VP, Global Communications and European Investor Relations
M +33 (0)6 4516 7099
communications@valneva.com
|
Joshua Drumm, Ph.D.
VP, Global Investor Relations
M +001 917 815 4520
joshua.drumm@valneva.com
|
|
|
1 U.S. CDC Advisory Committee (ACIP) Recommends Use
of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ® -
Valneva
- 2024_03_04_VLA_Cowen_Kempen_Curtain_Raiser_EN_Final
Valneva (LSE:0OB3)
Historical Stock Chart
From Apr 2024 to May 2024
Valneva (LSE:0OB3)
Historical Stock Chart
From May 2023 to May 2024